Arcutis Biotherapeutics EVP Matsuda sells $32,123 in stock By Investing.com

Masaru Matsuda, Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics, Inc. (), sold 1,230 shares of the company’s common stock on August 3, 2026. The total value of these transactions amounted to $32,123.

The shares were sold at a weighted average price of $26.1168 per share, with individual transaction prices ranging from $25.72 to $26.69. According to the filing, this sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units. The stock currently trades at $27.10, reflecting a remarkable 76% gain over the past year.

Following these transactions, Mr. Matsuda directly holds 126,171 shares of Arcutis Biotherapeutics common stock. This reported total includes 712 shares that were purchased under the Issuer’s Employee Stock Purchase Plan on May 31, 2026. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts predicting profitability this year. For deeper insights, investors can access a comprehensive Pro Research Report on ARQT, one of 1,400+ available on the platform.

In other recent news, Arcutis Biotherapeutics reported a significant increase in its second-quarter revenue for 2026, surpassing market expectations. The company announced net product revenue of $129.9 million, exceeding the forecasted $118.47 million. This marks a 59% increase from the previous year and a 23% rise from the first quarter, indicating strong growth. Additionally, Arcutis Biotherapeutics achieved profitability during this period, a notable milestone for the company. These developments have positively impacted investor sentiment. The earnings report reflects the company’s robust performance in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.